Non-formulary **belimumab (Benlysta)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

- Prescriber is a Rheumatologist
- **AND**
- Patient has a diagnosis of active systemic lupus erythematosus (SLE) with positive antinuclear antibody (ANA) and/or anti-double-stranded deoxyribonucleic acid (anti-dsDNA) and/or Sjogren’s antibody (SSA or SSB) [*these are tests used to diagnose lupus*]
- **AND**
- Patient is dependent on corticosteroid therapy **OR** documented contraindication or intolerance to corticosteroid therapy
- **AND**
- Patient has a documented treatment failure after at least a 60-day course, or an intolerance/contraindication to, each of the following:
  - At least one nonsteroidal anti-inflammatory drug [NSAID] (such as aspirin, ibuprofen, naproxen, etodolac, or meloxicam)
  - At least one antimalarial (hydroxychloroquine or chloroquine)
  - At least one immunomodulator (cyclophosphamide, azathioprine, methotrexate, or mycophenolate)
- **OR**
- Patient is already stable on the drug